Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02308137
Other study ID # Domperidone_MS01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 2015
Est. completion date January 3, 2020

Study information

Verified date February 2020
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to determine if Domperidone in a dose of 40 mg daily can prevent worsening of walking ability in people secondary progressive MS. The number of participants in this study will be 62. A maximum of 75 people with secondary progressive MS will be included. Each patient will be followed for 12 months from inclusion. Domperidone is a medication which has been shown to increase levels of the hormone prolactin. The best understood function of prolactin is the stimulation of milk production in women after delivery. However, the increase in prolactin levels seen in patients treated with standard doses of Domperidone (in doses of up to 80mg per day) usually does not lead to clinical symptoms. Prolactin has been shown to improve myelin repair in mice. Domperidone therefore may also improve myelin repair in people with MS. Domperidone is currently approved in Canada to treat slow moving bowels and nausea, for instance in patients with Parkinson's Disease or Diabetes Mellitus, where too slowly moving bowels can cause constipation. Domperidone is available as a tablet that is usually taken four times per day. Doses up to 80mg per day may be used but we estimate that a dose of only 40mg daily will be needed to stimulate myelin repair. Domperidone is usually well tolerated.


Description:

Primary objective

To demonstrate non-futility of domperidone for reducing progression of disability, as measured with the timed 25 foot walk (T25FW), in secondary progressive Multiple Sclerosis (SPMS).

Secondary objectives

- To assess the safety of domperidone in the study population for the duration of the study.

- To assess the effect of domperidone on hand dexterity as measured with the 9HPT

- To assess the effect of domperidone on cognition, as measured with the SDMT

- To assess the effect of domperidone on health related quality of life, as measured with the MSQOL-54

- To assess the effect of domperidone on fatigue, as measured with the MFIS

- To establish the Simon-2-stage model as a study model in MS research. The application of this methodology to studies in progressive MS will have important consequences for the design and conduct of clinical and translational research in progressive MS, in particular for phase II trials in progressive MS


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date January 3, 2020
Est. primary completion date January 3, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- written informed consent obtained

- with Multiple Sclerosis, and with secondary progressive disease course

- screening Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5 inclusive

- screening timed 25 foot walk (average of two trials) lof 9 seconds or more

Exclusion Criteria:

- Long QT interval, defined as corrected QT interval of more than 470 msec in men and more than 450 msec in women on baseline ECG

- Patients with known long-QT syndrome

- Patients with known ventricular arrhythmia

- Patients with a known electrolyte disturbance

- Patients undergoing treatment with drugs that increase the QTc interval

- Patients undergoing treatment with drugs that inhibit CYP3A4, in particular: Ketoconazole, Fluconazole, Erythromycin, Clarithromycin, Ritonavir

- Patients with a history of breast cancer or carcinoma in situ

- Patients with known renal insufficiency

- Patients with known allergy or other intolerability to domperidone

- Patients currently using Fampridine or 4-aminopyridine

- Patients planning to start Fampridine or 4-aminopyridine during the study period

- Patients planning to start Baclofen or Tizanidine during the duration of the study

- Patients planning to increase or decrease their dose of Baclofen or Tizanidine during the study period

- Patients planning to receive treatment with Botulinum toxin in the leg muscles during the duration of the study

- Patients with a significiant hepatic impairment

- Patients with a prolactinoma

- Patients in whom gastrointestinal stimulation could be dangerous

- Patients using MAO inhibitors

- Patients with a history of breast cancer

- Pregnant or breast-feeding women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Domperidone
Simon-2-stage design for domperidone futility

Locations

Country Name City State
Canada Calgary MS Clinic at Foothills Medical Centre Calgary Alberta

Sponsors (2)

Lead Sponsor Collaborator
University of Calgary Alberta Innovates Health Solutions

Country where clinical trial is conducted

Canada, 

References & Publications (10)

Franklin RJ, ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012 Nov 5;8(11):624-34. doi: 10.1038/nrneurol.2012.200. Epub 2012 Oct 2. Review. — View Citation

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012 Nov 5;8(11):647-56. doi: 10.1038/nrneurol.2012.168. Epub 2012 Sep 25. Review. — View Citation

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):938-52. Review. — View Citation

Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012 Apr;122(4):1180-8. doi: 10.1172/JCI58649. Epub 2012 Apr 2. Review. — View Citation

Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C, Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006 Dec;129(Pt 12):3165-72. Epub 2006 Aug 18. Erratum in: Brain. 2007 Mar;130(Pt 3):879. — View Citation

Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006 Apr;5(4):343-54. Review. — View Citation

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 Sep;42(3):379-82. — View Citation

Tselis A, Khan OA, Lisak RP. Approaches to neuroprotective strategies in multiple sclerosis. Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5. Review. — View Citation

Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989 Dec;112 ( Pt 6):1419-28. — View Citation

Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler. 2013 Jan;19(1):15-23. doi: 10.1177/1352458512458555. Epub 2012 Aug 29. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Timed 25-Foot Walk (T25W) quantitative ambulation performance test up to 12 months
Secondary 9-Hole Peg Test brief, standardized, quantitative test of upper extremity administered at baseline, one month, 6 months, and 12 months
Secondary Symbol Digit Modalities Test measures cognitive processing speed and working memory administered at baseline, one month, 6 months, and 12 months
Secondary Functional Systems and Expanded Disability Status Scale (EDSS) EDSS is the standard measure of neurologic impairment that is used to describe disability in MS. The neurological assessment comprises seven functional systems. administered at baseline, one month, 6 months, and 12 months
Secondary Modified Fatigue Impact Scale (MFIS) structured, self-report questionnaire with 21 itmes concerning how fatigue impacts patient's life administered at baseline, one month, 6 months, and 12 months
Secondary Multiple Sclerosis Quality of Life Scale 54 item version 54-item multidimensional health-related quality of life measure that combines both generic and MS-specific items administered at baseline, one month, 6 months, and 12 months
See also
  Status Clinical Trial Phase
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT02273635 - Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Phase 1/Phase 2
Recruiting NCT05961644 - Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). Phase 2/Phase 3
Completed NCT06436131 - The Effects of In-phase Bilateral Exercise in People With Progressive Multiple Sclerosis N/A
Recruiting NCT05013463 - Hydroxychloroquine and Indapamide in SPMS Phase 2
Recruiting NCT04918225 - Motor Asymmetry in Progressive Multiple Sclerosis Patients
Completed NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Phase 2
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Terminated NCT02430532 - BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) Phase 3
Completed NCT00888277 - Bayer/Cognitive Assessments With Multiple Sclerosis Subjects N/A
Completed NCT05663853 - An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Recruiting NCT05168384 - Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Phase 1/Phase 2
Completed NCT02305264 - Imaging of Intracerebral Inflammation in MS N/A
Terminated NCT00468611 - Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Phase 3
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Completed NCT05357833 - Novel Imaging Markers in SPMS Early Phase 1
Not yet recruiting NCT06390930 - Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS N/A
Completed NCT02506751 - Open-label Study of Liothyronine in MS Phase 1
Completed NCT00587691 - Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT04260711 - Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). N/A